Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Naoki Sasahira

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0672-7214; OpenAlex author ID A5010319344. Sources: OpenAlex.

Their work

Papers
96 (first author 1, last author 37)
Trials
0
Grants
0
Labs led
1
Collaborators
183
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 7 papers · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 6 papers · 2021: 11 papers · 2022: 11 papers · 2023: 13 papers · 2024: 5 papers · 2025: 13 papers · 2026: 15 papers

Papers 50 of 96

  1. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. Co-author DOI 10.1002/bcp.70611↗
  2. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Last author DOI 10.1002/deo2.70154↗
  3. Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.1002/ijc.70637↗
  4. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Last author DOI 10.1002/jhbp.70058↗
  5. Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-026-03201-0↗
  6. Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-… Co-author DOI 10.1007/s10637-026-01632-0↗
  7. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  8. Circulating SDF4 as a potential diagnostic marker for early-stage pancreatic cancer Co-author DOI 10.1038/s41598-026-63925-x↗
  9. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Last author DOI 10.1093/jjco/hyaf194↗
  10. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  11. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. Last author DOI 10.1159/000550483↗
  12. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  13. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  14. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  15. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  16. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Last author DOI 10.1002/deo2.70014↗
  17. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. Last author DOI 10.1007/s10147-025-02796-0↗
  18. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  19. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2025.06.013↗
  20. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  21. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
  22. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  23. [Multidisciplinary treatment for borderline resectable pancreatic cancer]. Last author DOI 10.11405/nisshoshi.122.810↗
  24. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  25. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  26. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
  27. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Last author DOI 10.2169/internalmedicine.3577-24↗
  28. Factors Affecting Delayed Recovery from Neutropenia in Patients with Pancreatic Cancer Receiving Gemcitabine plus Nab-Paclitaxel. Co-author DOI 10.7150/jca.107359↗
  29. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT s… Co-author DOI 10.1002/cncr.35343↗
  30. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. Last author DOI 10.1002/deo2.360↗
  31. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  32. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  33. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Last author DOI 10.1093/jjco/hyae028↗
  34. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  35. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Last author DOI 10.1002/deo2.205↗
  36. Outcomes of pancreatic cancer with liver oligometastasis. Last author DOI 10.1002/jhbp.1184↗
  37. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Last author DOI 10.1007/s00464-022-09836-0↗
  38. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  39. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  40. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Last author DOI 10.1016/j.pan.2023.02.002↗
  41. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  42. Outcomes of lung oligometastasis in pancreatic cancer. Last author DOI 10.1093/jjco/hyad111↗
  43. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
  44. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  45. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Last author DOI 10.2169/internalmedicine.0730-22↗
  46. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Last author DOI 10.3390/cancers15020358↗
  47. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  48. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Last author DOI 10.1016/j.pan.2022.04.003↗
  49. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Last author DOI 10.1093/jjco/hyac145↗
  50. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗

Closest collaborators

The 25 strongest of 183 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masato Ozaka · 64 shared papers, 2018–2026 · strength 11.41
  2. Takashi Sasaki · 56 shared papers, 2011–2026 · strength 8.84
  3. Tsuyoshi Takeda · 44 shared papers, 2015–2026 · strength 7.39
  4. Takafumi Mie · 39 shared papers, 2020–2026 · strength 6.73
  5. Takaaki Furukawa · 33 shared papers, 2020–2026 · strength 5.60
  6. Takeshi Okamoto · 26 shared papers, 2021–2026 · strength 4.88
  7. Akiyoshi Kasuga · 27 shared papers, 2020–2025 · strength 3.97
  8. Yu Takahashi · 21 shared papers, 2020–2026 · strength 3.44
  9. Masato Matsuyama · 25 shared papers, 2019–2023 · strength 3.42
  10. Yosuke Inoue · 18 shared papers, 2020–2026 · strength 3.10
  11. Atsushi Oba · 16 shared papers, 2022–2026 · strength 2.83
  12. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  13. Yoshihiro Ono · 12 shared papers, 2021–2026 · strength 2.10
  14. Hiromichi Ito · 11 shared papers, 2022–2026 · strength 2.02
  15. Aya Maekawa · 10 shared papers, 2023–2026 · strength 1.95
  16. Manabu Takamatsu · 10 shared papers, 2021–2026 · strength 1.67
  17. Makoto Ueno · 9 shared papers, 2018–2026 · strength 1.30
  18. Hiroki Nakagawa · 7 shared papers, 2022–2025 · strength 1.25
  19. Hiroshi Ishii · 7 shared papers, 2018–2026 · strength 1.23
  20. Takashi Yokokawa · 6 shared papers, 2021–2026 · strength 1.23
  21. Yousuke Nakai · 23 shared papers, 2011–2026 · strength 1.23
  22. Tsuyoshi Hamada · 13 shared papers, 2011–2026 · strength 1.15
  23. Kojiro Omiya · 6 shared papers, 2023–2025 · strength 1.12
  24. Akio Saiura · 7 shared papers, 2020–2024 · strength 1.05
  25. Yukari Suzuki · 4 shared papers, 2025–2026 · strength 1.01

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.